Autoimmune diseases are a heterogeneous group of disorders characterized by an altered reactivity of the immune system against self antigens. The majority of patients show a chronic clinical course, responsive to immunosuppressive and immuno dulating therapies. However there is a subset of cases that show a rapidly progressive disease, resulting in a signifi cant disability and a potential shortening of life time. For these patients, innovative and more effective treatments strategies are needed. Haematopoietic stem cells transplantation (HSCT) has been used for the treatment of autoimmune disorders based on results obtained in animal models [1, 2] . Allogeneic transplantation was shown to have the potential to transfer the autoimmune disorder in healthy animals [3, 4] , but was also able to induce long lasting remission in affected animals [5, 6] . Nevertheless autologous transplantation has been proved to determine clinical remission in induced diseases, even if a minor rate when compared to allogeneic [7] . Meanwhile, the evidence of disease remission of concomitant autoimmune disorders in patients treated with HSCT for haematological malignancies showed that this procedure should be considered a valuable option in unresponsive patients. The fi rst experiences were performed 15 years ago. At the end of the 1990's, selection criteria for these patients based on the fi rst reported data, were discussed [8] .
Patients must have to failed one or more conventional line of therapies, have a poor prognosis in terms of mortality and/or disability progression and be without any irreversible organ failure. A recent analysis of the EBMT database pointed out that the diagnosis is the major factor determining both the transplant-related mortality (TRM) and progression-free survival (PFS) [9] . The experience of the transplanting Centre has a benefi cial impact on the TRM, whilst younger age and transplants performed after 2001 show a better PFS. Data reported to the EBMT database (Table 1) showed that the most frequent diseases that have been transplanted are Multiple Sclerosis (MS) and Systemic Sclerosis (SSc). In MS, progression free survival has been reported to range from 50 to 70% at 5 years after HSCT. The most frequent conditioning regimen adopted in Europe is the association of BEAM and ATG, an intermediate-intensity scheme able to completely suppress MRI activity for at least 2 years in most of patients. Mortality has dropped in the last years from a relevant 7.3% to 1.2%, due to a better transplant management and patients selection [10] . In rapidly progressive SSc 5-years mortality is estimated to be 40-50% [11] . The most commonly used conditioning regimen in Europe is Cyclophosphamide (200 mg/Kg) and ATG. In these patients, progression free survival after HSCT has been showed to be above 50% at 5 years. Furthermore, the use of high intensity conditioning regimens does not seem to offer special advantages over lower intensity schedules for this disease. The distribution of transplants per year shows a drop of activity in SLE and especially in infl ammatory arthritis, following the introduction of new biological agents after 2000. The emergence of pharmacological resistance in long-term treatments may suggest a possible renewal of the activity also in this subset of patients. In chronic infl ammatory bowel diseases (IBD) an increasing activity has also been shown in the last 6 years. HSCT is able to provide a high rate of long-term, immunosuppression-free remissions in AD patients resistant to conventional therapies. Appropriate selection of patients is crucial for providing the best risk-benefi t equipoise. Evidence of effectiveness and careful assessment of toxicity is expected from ongoing and future prospective clinical trials.
PLENARY SESSION 1
Mechanisms of immunologic tolerance

Sergio Romagnani
University of Florence, Florence, Italy Immunological tolerance can be defi ned as the failure to respond to an antigen, which is induced by prior exposure of the specifi c lymphocyte to the same antigen under particular micro-environmental conditions. Tolerance of T lymphocytes may occur in the central lymphoid organ where T cells develop, i.e. the thymus (central tolerance), or at level of secondary lymphoid organs (peripheral tolerance). Central tolerance in the thymus is mainly due to a negative selection of T cells showing high affi nity for self peptides, which undergo apoptotic cell death, as well as to the development of T regulatory (Treg cells). Self peptides are presented to T cells by medullar epithelial cells, which are able to express on their surface even peptides present in different organs and tissues (promiscuous gene expression), a process which is regulated by the autoimmune regulatory gene (AIRE). However, not all T cells showing affi nity for self peptides are removed in the thymus and those that survive to negative selection colonize into peripheral lymphoid organs. At this level, other mechanisms are operating in order to provide further protection towards responses against self. These mechanisms are known as anergy, immune deletion and immune regulation. T-cell anergy occurs when T cells encounter their specifi c peptide presented by cells which lack the co-stimulatory molecules or express co-stimulatory molecules that interact on T cells with the inhibitory molecule CTLA-4. Immune deletion occurs as a consequence of a powerful stimulation that induces the expression on T cells of the apoptotic ligand FasL and of its receptor Fas (activation induced cell death). Immune regulation results from the activity of Treg cells, which originate in the thymus (natural Tregs), but also in the periphery (adaptive Tregs) and are mainly characterized by the expression of the transcription factor Foxp3. When, despite all these protective mechanisms, activation of effector T cells occurs, an autoimmune responses takes place. Autoimmune disorders may develop spontaneously because of a genetic defect that alters important mechanisms of central or peripheral tolerance, such as AIRE, Foxp3, or genes of the apoptotic cascade or as consequence of the activity of environmental factors. Among these latter, infections certainly play the most important role. Uncontrolled Th1-and/ or Th17-polarized responses to some microbial products can indeed result in autoimmune reactions in genetically susceptible individuals. The respective role of these two populations of T-cell effectors will be discussed. One emerging therapeutic approach that is being evaluated for aggressive forms of immune-mediated disorders is immune ablation followed by autologous haematopoietic stem cell transplantation (HSCT). In this presentation I will discuss the current clinical and laboratory evidence that supports the notion that a reconditioning of the immune system is the basis for the protracted remission of autoimmune disease observed after HSCT. The rationale of using HSCT in autoimmune disease is to purge the existing immune system and regenerate a new and healthy repertoire of immune cells. However, the notion of an immune "resetting" remained conjectural until the regeneration of a new T cell repertoire was demonstrated after autologous haematopoietic stem cell transplantation in patients with MS (1) and subsequently confi rmed in patients with SLE (2, 3) . The renewed T cell repertoire was more clonally diverse than pretreatment and was found in connection with a boost in thymic output of naïve T cells ("thymic rebound") during long-term immune reconstitution. These studies have challenged the previous assumption that the effects of HSCT on the course of disease were simply the result of profound immunosuppression. Although reconstitution of a new and more diverse T cell repertoire is expected to contribute to the mode of action, it is probably insuffi cient to explain a maintained self-tolerance post-therapy, since pathogenic lymphocytes could also be regenerated from haematopoietic progenitor cells, or from residual mature lymphocytes surviving high-dose immunosuppressive treatment (4) . This prompted others and us to hypothesize that restoration of self tolerance could be mediated by the normalization of immune regulatory mechanisms. In an animal model of multiple sclerosis, there was an increase of CD4+CD25+ T cells after syngeneic bone marrow transplantation and this was seen in connection with attenuation of active disease and protection from induction of relapses (5) . In humans, enumeration of CD4+CD25[high] T cells in juvenile idiopathic arthritis patients after AHSCT showed recovery of the pre-treatment frequency of Tregs at 6 months post-transplant, and a continued increase for the remaining 12-month follow-up period (6) . Our data in patients with MS show surges of CD4+FoxP3+ as well as other immune regulatory cell populations post-therapy (Abrahamsson et al., submitted). Based on the current evidence, I propose that the mechanisms underlying restoration of self tolerance following HSCT include two modalities of immune resetting: immune resetting "Type I" consisting of T cell/B cell repertoire replacement; and immune resetting "Type II", consisting of restoration of immune regulation. These mechanisms are not mutually exclusive and are probably complementary. Their relative contribution to the therapeutic effect may depend from the transplantation regimen and other factors that infl uence immune reconstitution posttransplantation. Understanding in which proportion "Type I" and "Type II" immune resetting each contribute to the reinstatement of self tolerance following HSCT requires further investigation.
CHOICE OF CONDITIONING REGIMEN Dr John A. Snowden Director of BMT Programme, Sheffi eld Teaching Hospitals and University of Sheffi eld, UK
Haematopoietic stem cell transplantation (HSCT) has evolved as a clinical treatment for severe and resistant autoimmune diseases after years of animal studies and serendipitous observations. 1 The principles have been based on traditional HSCT practice, principally in oncology and aplastic anaemia. Conditioning regimens, an essential part of HSCT, refer to the preparatory cytotoxic therapy that precedes the infusion of the stem cell transplant product, and consist of chemotherapy, radiotherapy and serotherapy or combinations thereof. In autologous HSCT, where there is no risk of immunological graft rejection, the conditioning serves the purpose of a high intensity cytotoxic regimen following which HSCT provides haematopoietic rescue. In allogeneic HSCT, the regimen must also be sufficiently immunosuppressive to permit successful engraftment. In the early days of HSCT, conditioning regimens were based on the premise of delivering intensive cytotoxic chemotherapy at or close to the point of immuno-myeloablation. In recent years non-myeloablative or reduced intensity conditioning has been increasingly utilized in allogeneic HSCT in a desire to limit toxi city whilst delivering intense immunosuppression. The term 'nonmyeloablative' has been extended into the autologous setting with a similar goal of immunoablation with limited toxicity. In 1997, the fi rst proposals for clinical trials in autoimmune disease were published by Tyndall & Gratwohl on behalf of the EBMT and EULAR. 2 Given the inability to perform de novo phase I studies, and a desire to limit the number of regimens, they proposed that centres restricted their initial studies to one of four standard HSCT regimens: Cyclophosphamide (Cy) 200 mg/kg +/-antithymocyte globulin, Cy 120 mg/kg + Total Body Irradiation (TBI), Busulphan 16 mg/kg + Cy 120 mg/kg, and the 'BEAM' regimen, commonly used in lymphoma. Although TBI had been the focus of many animal studies and had potential advantages, an excess of toxicity was acknowledged to be an issue. A subsequent analysis 3 of the fi rst 473 HSCT procedures in the EBMT autoimmune diseases registry confi rmed that the majority of centres had followed the initial four recommendations for conditioning regimen, with the most notable variation being the addition of serotherapy to combine targeted immunosuppression and in vivo purging of immune effectors. In this analysis, the conditioning regimens were divided into low, intermediate and high intensity regimens. Perhaps predictably, there was highly signifi cant relationship between effi cacy and intensity, but this was somewhat outweighed by the inverse relationship with toxicity as refl ected by treatment related mortality (TRM). In addition to the registry analysis, many phase I/II trials have now been published which have highlighted the effi cacy and safety issues. 1 There has been general recognition of the role of autologous HSCT as an effective means of controlling otherwise resistant autoimmune disease, but not a cure, with long term control requiring ongoing therapy, perhaps in a similar manner to low grade lymphoproliferative disorders. Attempts have been made to create disease specifi c conditioning regimens, based on targeting the disease process and there has been a reasonable emphasis on limiting the potential for toxicity and TRM. 4 In this respect there has been increasing recognition that total myeloablation may not necessarily provide the best balance between benefi ts and risks, and that autologous HSCT could be used to support safer, better tolerated forms of intensive immuno-ablation. 5 In addition, there has been considerable discussion about the role of TBI based regimens in certain diseases where radiation may exacerbate specifi c conditions and generic late effects. 6 Ultimately, the results of phase III trials should be available in scleroderma, multiple sclerosis and Crohn's disease to prove initial proof of principle of the future role of autologous HSCT in these diseases. In other diseases, and also in the allogeneic HSCT setting, where procedures have been rare, evidence will depend on well-analysed observational data, and, if possible, matched case control studies with the current best alternative non-HSCT treatment. The results of such studies will be the starting point for refi nement of the conditioning regimen from those originally proposed in 1997 into those that deliver the best effi cacy and safety balance of specifi c diseases. Given the relatively long-term prognosis of many autoimmune diseases, including those stabilised by HSCT, the evolving sub-speciality of 'late effects' will also be pivotal to choice of conditioning regimen.
7 Pharmaco-economic considerations related to the conditioning regimen will also be important for the delivery of care. 
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hematopoietic stem cell transplantation (HSCT). Autoreactive immune effector cells may be eliminated by allogeneic HSCT or regulatory immune mechanisms may dominate in the setting of mixed hematopoietic chimerism. Either of these mechanisms may result in remission of AID. The major risks associated with allogeneic HSCT are GVHD and opportunistic infections. Treatment-related mortality would be expected to be 10-15% or higher. The fi rst experiences in humans in understanding the effect of allogeneic HSCT on AID was from case reports or reports of small series of patients in which sustained remissions were observed. Relapses were also observed in a small number of patients. More recently the experience of allogeneic HSCT for AID was reviewed by EBMT (Daikeler et al., BMT, 2009 ). They noted that the overall response rate of the AID was 78%. TRM was 22% and overall survival was 70% at 2 years. The study was limited because of the heterogeneous patient population and missing data. However it was concluded that the study provided a basis for a carefully conducted prospective clinical trial.
In North America, a cross-sectional study was done of MS patients who underwent allogeneic HSCT for a haematological malignancy. Eleven patients were evaluated in Seattle. Three patients had disease activity after transplant, 2 of whom later stabilized. All other patients remained neurologically stable. All patients beyond 5 years after HSCT were negative for oligoclonal bands. A patient who died 5 months after HSCT had an autopsy and the brain was evaluated. There was evidence of infl ammatory cells with persisting demyelination and axonal damage. Another patient died at 3.5 years after HSCT with no evidence of disease activity in the brain. Early neurological events may occur after transplant but long-term survivors appear to be neurologically stable. A registry is being established to identify MS patients undergoing transplantation so they can be followed long-term for outcomes. The registry will also identify and follow patients transplanted from donors with MS. A prospective phase II clinical trial of allogeneic HSCT for systemic sclerosis has being proposed (ALLSTAR). It will also include a concurrent cohort of patients that is not transplanted. Patients will receive a reduced intensity conditioning regimen. Mechanistic studies will evaluate the effect of transplant on the disease-related fi brosis and vasculopathy. Studies have been performed on skin biopsies to help differentiate the scleroderma-related pathology from chronic GVHD (Fleming J. et al., PLOS One, 2009).
ORAL SESSION: DISEASE SPECIFIC CLINICAL EXPERIENCE: MULTIPLE SCLEROIS AND SYSTEMIC SCLEROSIS
EUROPEAN ACTIVITY IN MS
Gianluigi Mancardi
Gianluigi Mancardi* and Riccardo Saccardi** *Department of Neuroscience, Ophthalmology and Genetics, University of Genoa, Italy **Bone Marrow Transplantation Unit, Careggi Hospital, University of Florence, Italy
In the last years, intensive immunosuppression followed by autologous transplantation of hematopoietic stem cells (AHSCT) has been proposed as a possible strategy for the treatment of severe autoimmune disorders, including multiple sclerosis (MS). The rationale for AHSCT derives from the possibility to eradicate self reactive immune cells by immunosuppression followed by full immune reconstitution after the engraftment of the autologous haematopoietic stem cells. Beyond its immunosuppressive potential, AHSCT may also be benefi cial for the possible "resetting" of the immune system due to a "de novo" regeneration of the T cell compartment, which could become tolerant against self-antigens, possibly for an extended period of time. The results appear to be particularly impressive in rapidly evolving severe MS cases unresponsive to conventional therapies. In these cases, defi ned also malignant forms of MS, numerous European groups convincingly demonstrated the capacity of AHSCT to suppress the progression of the disease, with an unexpected relevant improvement of the neurological conditions lasting for a long period of time. The establishment of AHSCT as a rescue therapy in rapidly evolving MS cases unresponsive to the other conventional therapies is the most important achievement obtained in Europe in these years. The phase 2 study (ASTIMS), comparing AHSCT vs. Mitoxantrone with a MRI primary endpoint, is ongoing in Europe. 21 cases have been enrolled till now, and, for the lack of accrual, the study will be probably soon terminated. The evaluation of difference in the number of new T2 lesions between the two groups will add new relevant data on the activity of AHSCT. Numerous other phase I/II studied have been carried out in the mean time in Europe, especially evaluating the clinical characteristics of the patients who can take advantage from AHSCT. A new study, with a clinical endpoint, in patients that failed the conventional therapies, is now discussed by the neuro-haematological community interested in this therapeutic strategy.
HEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT) FOR MULTIPLE SCLEROSIS (MS) IN NORTH AMERICA
Harold Atkins
Ottawa Health Research Institute, Ottawa, Canada
North American efforts in the fi eld of HSCT for MS take the form of registry data and ongoing clinical trials. The CIBMTR has collected data on 150 patients that have undergone autologous HSCT for MS during the 12 years between 1996 and 2008. Most patients underwent transplantation during the secondary progressive phase of MS and had a baseline EDSS score of between 3.0 and 8.0. The 3 year overall survival of this cohort was 94%. Currently, a collaborative effort between the CIBMTR and the EBMT autoimmune disease committees is developing a protocol to examine the long-term MS outcomes of these patients. In addition, there are several ongoing clinical trials of autologous HSCT for patients with MS. The inclusion criteria used for each trial will select patients with different disease characteristics and each trial has a different treatment strategy, refl ected in the differing chemotherapy dose intensities used in their conditioning regimens. An analysis is underway to determine the MS outcomes of recipients of allogeneic HSCT for a malignancy but coincidentally have MS. A registry is being established to collect clinical data and samples from similar patients undergoing allogeneic HSCT in the future. Two trials have been registered with ClinicalTrials. gov that examines the role of allogeneic HSCT for MS.
Comparing and contrasting the MS outcomes following HSCT using the data available from these trials provide clues to understanding how the baseline MS stage and activity, the transplant conditioning regimen, the graft source and graft manipulations affect the outcome of MS following HSCT, a necessity before a defi nitive Phase III randomized clinical trial comparing HSCT to other MS therapies could be contemplated. Background: SSc, affecting around 250,000 people in Europe, is responsible for signifi cant morbidity; with a 5-year mortality around 40-50% in case of rapidly progressive diffuse cutaneous SSc. Autologous Hematopoietic stem cell transplantation (HSCT) has been employed since 1996 as a new therapeutic strategy in SSc patients with a poor prognosis. Objectives: To review the short and long term data from the various European phase I-II studies and from the EBMT registry that aimed to analyse the effects of HSCT on survival, skin and major organ function in patients (pt) with severe diffuse cutaneous SSc. Based on these results, to present the European ongoing prospective, controlled, randomized ASTIS trial designed to evaluate if HSCT is superior over 12 monthly i.v. cyclophosphamide (conventional treatment) in terms of safety and effi cacy and to assess potential predictive factors of response in SSc patients at risk of major organ failure or early mortality: primary endpoint is event-free survival (survival until death or development of major organ failure during 2 years follow-up) and progression-free survival (PFS) is the main secondary endpoint. Results: In October 2009, 225 HSCT for SSc were reported in the EBMT registry database. The projected 5-year survival rate of the fi rst 175 HSCT in SSc pts was 76% (95% CI: 69%-83%), much higher than observed for non treated patients, with a 6% (95% CI: 2%-10%) Transplant Related Mortality (TRM) and a 55% (95% CI: 46%-64%) PFS. Several phase II studies have shown that autologous HSCT in selected patients with severe diffuse cutaneous SSc results in a) sustained and striking improvement of both clinical and histological skin fi brosis and of functional status (SHAQ and performance status) within the 1st after HSCT and b) stabilisation of organ (lung, heart and kidney) functions with durable responses in two thirds of patients up to 7 yrs after HSCT. The ongoing ASTIS trial has completed the recruitment of 156 SSc patients with early active diffuse SSc, with or without major organ involvement: 79 patients randomized to the HSCT arm have undergone mobilization with cyclophosphamide 2x2 g/m 2 , conditioning with cyclophosphamide 200 mg/kg, rbATG 7.5 mg/kg, followed by reinfusion of CD34+ selected autologous HSCT and 77 patients are treated with 12x monthly i.v. bolus cyclophosphamide 750 mg/m 2 . No unexpected toxicities have yet been observed in either arm with a median follow-up of 33 months (range 1-91). Results from this trial will not be obtained before 2011.
EUROPEAN ACTIVITY IN SYSTEMIC SCLEROSIS (SSC)
Dominique
Conclusion:
Since 2000 in Europe, there has been better selection and improved clinical management of the SSc patients accounted for signifi cant decreased TRM and improved overall PFS after HSCT. The centre's experience was an independent variable in determining the TRM and the overall survival after HSCT in SSc. Promising clinical results from HSCT in SSc, a new therapeutic approach aiming at resetting tolerance, will be confi rmed by those from the still ongoing ASTIS trial and by further complementary analysis of the immunological determinants of the observed clinical responses. The SCOT (Scleroderma Cyclophosphamide or Transplantation) Trial is a randomized, multi-center, 2-arm study comparing high-dose immunosuppressive therapy using total body irradiation, cyclophosphamide (CY), and ATGAM followed by autologous transplantation with auto-CD34+HPC to intravenous 12-monthly pulse CY for the treatment of severe systemic sclerosis. There are 9 transplant/rheumatology centers (8 in the U.S. and 1 in Canada) which recruit and treat patients in both arms of the study with an additional ~20 rheumatology centers which refer eligible subjects and provide monthly CY infusions. As of June, 2009, 156 subjects have been enrolled for screening and 54 have been randomized to receive either IV monthly CY or high-dose immunoablative therapy followed by autologous hematopoietic cell transplantation. The reasons for enrolled patients not proceeding to randomization are outlined in another session of this meeting. Of the 54 randomized subjects, 2 were withdrawn shortly after randomization for safety reasons. As of the end of May, 2009, demographic features on 50 randomized subjects included: 74% female, 82% white and mean age 46.4 years. At baseline, the mean FVC value was 76.8% predicted, the mean Hbadjusted DLCO (Crapo-Morris formula) was 53.4% predicted and the mean modifi ed Rodnan skin score was 32.2. A total of 74 post-randomization serious adverse events (SAEs) were reported among 26 subjects. This includes a combined total of fi ve deaths occurring among randomized subjects in both study arms and two additional deaths prior to randomization. Using the NCI Common Terminology Criteria for Adverse Events (AEs), which categorizes events by severity on a 1-5 scale with 1 = mild and 5 -death, the protocol captures Grade 2 events and above for all subjects except for those in the transplant arm which captures Grade 3 events and above from the start of conditioning until day 60 post-transplant. For all treatmentrelated AEs for all randomized subjects, 375 events among 34 subjects were reported with 58% of subjects with Grade 2, 52% with Grade 3, 40% with Grade 4 and only 2% (1 subject) with Grade 5. That is, only one subject was felt to have died of a treatment-related cause. In terms of effi cacy endpoints, treatment group differences are not anticipated until at least 4 years after randomization. The study remains open and is actively recruiting. Grant support is provided by award AI05419, NIAID/NIH.
AUTOLOGOUS TRANSPLANTATION FOR SYSTEMIC
ORAL SESSION: DISEASE-SPECIFIC CLINICAL EXPERIENCE -SYSTEMIC LUPUS ERYTHEMATOSUS, CROHN'S AND CYTOPENIAS
STEM CELL TRANSPLANTATION IN SLE
David Jayne
Renal Unit, Addenbrookes Hospital, Cambridge, UK Systemic lupus erythematosus (SLE) is a heterogeneous, multi-system, disease usually responsive to treatment with corticosteroids and immune suppressives. However, conventional therapy is not curative and many patients pursue a relapsing course with increasing risk of irreversible drug toxicity and disease related damage. A further consequence of a chronic disease course is the greatly increased risk of cardiovascular disease, and to a lesser extent, malignancy. Biologic therapies have demonstrated effi cacy and are likely to improve disease control and permit reduced steroid exposure but are also not curative. Autologous stem cell transplantation (ASCT) offers the potential to improve long-term outcomes in those with a poor prognosis. Preliminary phase II and registry studies in 150 patients have usually employed non-myeloablative conditioning with positive CD34 cell selection. Apparently similar results have also been obtained with immunoablative regimens without stem cell rescue, and occasional allogeneic stem cell transplant procedures have been performed. The studies have highlighted the potential long term effi cacy but also dangers of ASCT with a fi rst year mortality of 2-13%. ASCT has resulted in prolonged loss of autoreactive and an increase in regulatory T cells and normalisation of the B cell repertoire that parallel the clinical response. Patient selection is important but complex and the infl uence of ASCT on long-term outcomes, such as cardiovascular risk, is unknown. Disease relapse occurs in up to one third after ASCT but the consequences of relapse and role of remission maintenance strategies is unknown. An ongoing registry study will report the outcome of ASCT in 89 SLE patients registered with the EBMT. Phase III trials have encountered recruitment problems and the role of ASCT in routine care remains undetermined. The potential for allogeneic mesenchymal stem cells to infl uence lupus activity has been reported in animal models and one small clinical study.
